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Epidemiological studies suggest a direct link between melanoma and Parkinson’s disease (PD); however, the underlying molecular basis is
unknown. Since mutations in Parkin are the major driver of early-onset PD and Parkin was recently reported to play a role in cancer
development, we hypothesized that Parkin links melanoma and PD. By analyzing whole exome/genome sequencing of Parkin from 246
melanoma patients, we identified five non-synonymous mutations, three synonymous mutations, and one splice region variant in Parkin in
3.6% of the samples. In vitro analysis showed that wild-type Parkin plays a tumor suppressive role in melanoma development resulting in
cell-cycle arrest, reduction of metabolic activity, and apoptosis. Using a mass spectrometry-based analysis, we identified potential Parkin
substrates in melanoma and generated a functional protein association network. The activity of mutated Parkin was assessed by protein
structure modeling and examination of Parkin E3 ligase activity. The Parkin-E28K mutation impairs Parkin ubiquitination activity and
abolishes its tumor suppressive effect. Taken together, our analysis of genomic sequence and in vitro data indicate that Parkin is a potential
link between melanoma and Parkinson’s disease. Our findings suggest new approaches for early diagnosis and treatment against both
diseases.
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Melanoma, a melanocytic neoplasm, is responsible for 80% of
skin cancer mortality (Flaherty et al., 2012). Parkinson’s dis-
ease (PD) is the most common neurodegenerative movement
disorder; PD affects 1% of the population above 60 years of
age (Veeriah et al., 2010; Pan et al., 2011). Melanoma and PD* Corresponding author. Tel: þ972 3 640 9900, fax: þ972 3 640 5168.
E-mail address: carmitlevy@post.tau.ac.il (C. Levy).
http://dx.doi.org/10.1016/j.jgg.2016.05.005
1673-8527/Copyright 2016, Institute of Genetics and Developmental Biology, Chin
Limited and Science Press. All rights reserved.seem to have very different, even opposite, phenotypes at the
cellular level, as melanoma results from an uncontrolled,
extensive proliferation of cells, whereas PD is characterized by
degeneration and death of dopaminergic neurons. Intriguingly,
however, epidemiological studies indicate a potential rela-
tionship between melanoma and PD (Herrero Hernandez,
2009; Bertoni et al., 2010; Inzelberg et al., 2011; Liu et al.,
2011; Kareus et al., 2012), demonstrating that PD patients
and their relatives have a higher frequency of melanoma thanese Academy of Sciences, and Genetics Society of China. Published by Elsevier
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2009; Gao et al., 2011; Liu et al., 2011). Recently, Parkin
was also suggested as a genetic link between melanoma and
PD (Hu et al., 2016). However, the molecular mechanism
behind this link is still unknown.
Loss-of-function mutations in the Parkin gene (also
named PARK2, PRKN, MIM#602544) are responsible for
nearly 50% of early onset PD cases (Kahle and Haass, 2004;
Guo et al., 2008, 2010). Somatic mutations in the Parkin
gene are a known cause of autosomal recessive juvenile PD
(MIM#600116), in which a progressive death of neurons in
the substantia nigra takes place (Romani-Aumedes et al.,
2014). Alterations in the Parkin gene are also associated
with other diseases as demonstrated by MalaCards (Table
S1), such as lung cancer (MIM#211980), ovarian cancer
(MIM#167000) and susceptibility to leprosy (MIM#607572).
Parkin is an E3 ubiquitin ligase responsible for substrate
recognition in the ubiquitination process (Hershko and
Ciechanover, 1998) that leads to substrate degradation in
the proteasome (Hampe et al., 2006). The known substrates
of Parkin include cell cycle regulators, e.g., Cyclin D1 (Yeo
et al., 2012) and Cyclin E (Veeriah et al., 2010); apoptosis
mediators, e.g., Bax (Johnson et al., 2012) and Bcl2 (Chen
et al., 2010); proteins involved in synaptic transmission,
e.g., Synaptotagmin 11 (Kahle and Haass, 2004).
Abnormal Parkin function may underlie certain cancers
(Veeriah et al., 2010). The Parkin gene is located on chro-
mosome 6q in the fragile site FRA6E (Wang et al., 2009),
which is altered in a variety of human cancers (Letessier et al.,
2007). In the absence of Parkin expression, cancer cell lines
exhibit extensive proliferation and cell cycle abnormalities
(Veeriah et al., 2010; Yeo et al., 2012), while re-expression of
wild-type Parkin slows the growth of colorectal carcinoma
(Poulogiannis et al., 2010), breast cancer (Letessier et al.,
2007; Wang et al., 2009), and lung cancer (Poulogiannis
et al., 2010; Veeriah et al., 2010; Yeo et al., 2012) through
an unknown mechanism (Liu et al., 2011).
Since mutations in Parkin are the major driver of early-
onset PD (Lu¨cking et al., 2000; Kahle and Haass, 2004)
and there is evidence that Parkin is a key player in cancer
progression (Veeriah et al., 2010), we compiled and
analyzed sequences of Parkin from 246 melanoma patients.
We identified five melanoma-specific non-synonymous mu-
tations in Parkin in exons known to carry mutations in PD
patients. We showed that one of these mutations, E28K,
abolished the ubiquitination activity of Parkin. We further
demonstrated that Parkin is an inhibitor of cell cycle and an
apoptotic cell death driver in melanoma cells, whereas
Parkin-E28K abolishes Parkin tumor suppressive effects in
melanoma. Finally, in our attempt to uncover the role of
Parkin in melanoma, we identified potential Parkin sub-
strates in melanoma using immunoprecipitation followed by
mass spectrometry, and clustered the identified substrates by
functionality analysis. Our data suggest that Parkin links
between PD and melanoma and that Parkin may serve as a
diagnostic marker.RESULTSSomatic mutations of the Parkin gene in human
melanoma patientsTo determine whether mutations in Parkin gene are present in
melanoma, we compiled somatic mutation data from whole
exome/genome sequencing sources (Berger et al., 2012; Hodis
et al., 2012; Krauthammer et al., 2012; Nikolaev et al., 2012).
These data and the analysis methods were previously
described (Dutton-Regester et al., 2014). Our analysis revealed
mutations in 3.6% of the 246 samples analyzed. There were
six non-synonymous mutations, three synonymous mutations,
and one splice region variant (Table 1). The Parkin protein has
an N-terminal ubiquitin-like (UBL) domain, which is
responsible for the recognition of proteins destined for ubiq-
uitination. The C-terminal RING box includes two zinc fingers
separated by an in-between RING (IBR) domain that is
responsible for specific interaction with E2 enzymes (Imai
et al., 2000; Shimura et al., 2000). A linker region connects
the UBL and RING domains; this linker contains cleavage
sites for caspases 1 and 8 (Shimura et al., 2000; Kahle and
Haass, 2004) (Fig. 1A). The melanoma-specific mutations
are shown in Fig. 1A in relation to the protein domains.
Importantly, our analysis was only performed on point
mutations and small indels, and did not include large indels or
mutations of exon rearrangements. Therefore, it is possible
that Parkin mutational frequency in melanoma may be higher
than 3.6%.
The Parkin mutations commonly carried by PD patients
(Hedrich et al., 2004; Kay et al., 2010) were indexed by exon
and by type of mutation (i.e., point mutations, exon rear-
rangements, small deletions, and amplifications) and are rep-
resented in proportions to their amount in each exon (Fig. 1A,
upper panel). Known Parkin mutations span the entire gene.
Although mutations in different regions alter different
biochemical properties of the Parkin protein, apparently all
mutations disrupt the ability of Parkin to degrade substrates,
and thus manifest as loss-of-function mutations (Sriram et al.,
2005). Interestingly, the most unstable region of the fragile site
on chromosome 6q, FRA6E, is found in the region that con-
tains exons 2 through 8 of the Parkin gene (Letessier et al.,
2007), and this is the region where most melanoma and PD
mutations are observed (Fig. 1A). Exons 2 and 7 of the gene
were previously identified as mutational hot spots (Hedrich
et al., 2004). Remarkably, melanoma-specific somatic muta-
tions in Parkin appear in the same domains as the most
common germline PD mutations (Fig. 1A), supporting the
hypothesis of a genetic link between the two diseases.
The structure of Parkin has been determined by crystal-
lography (Protein Data Bank ID 4k95) (Trempe et al., 2013).
We used this structure to assess possible effects of the muta-
tions observed in melanoma patients on Parkin activity
(Fig. 1B). The E28K mutation is located in the helix of the
UBL domain. Based on a corresponding residue in NEDD8
protein, which is conserved and crucial for interaction with its
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371L. Levin et al. / Journal of Genetics and Genomics 43 (2016) 369e379partner NAE1 (Nedd8-activating enzyme E1, Protein Data
Bank ID 3gzn), the E28K mutation will lead to charge reversal
and, therefore, will likely disrupt binding of Parkin to sub-
strates (Fig. 1B, bottom-right enlargement square). The L112F
mutation is located in the linker between the UBL domain and
the first RING0 domain; this region is not resolved in the
crystal structure. The R275W mutation is located at the end of
the first helix in the second RING1 domain; R275 contacts a
residue located between helices 3 and 4. This mutation will
probably abolish this stabilizing contact and destabilize this
domain. The E300K mutation is located in RING1 domain and
is exposed to solvent in the crystal structure. This mutation
will likely lead to a steric clash with L187 in the RING0
domain. Finally, the C360S mutation is located in the IBR
domain and is involved in the binding of zinc. This mutation
will probably abolish zinc binding and significantly destabilize
the IBR structure. The finding that melanoma-specific muta-
tions in Parkin occur in similar regions to those in PD patients,
suggest that mutations in this E3 ubiquitin ligase might lead to
both diseases.Parkin reduces melanoma proliferation and promotes
apoptosisIn order to determine the biological role of Parkin in mela-
noma, we first examined the effect of Parkin overexpression
on melanoma clonogenic propensity. WM3314 and A375
melanoma cell lines were transiently transfected with a vector
for Parkin expression or an empty vector as a control and were
subjected to a colony formation assay. In both melanoma cell
lines, Parkin expression significantly decreased the number of
detected colonies (Fig. 2A). Further, Parkin overexpression
significantly attenuated metabolic activity of WM3314 and
A375 cells (Fig. 2B) and growth rate of these cells (Fig. 2C).
Moreover, overexpression of Parkin decreased cell cycle pro-
gression of WM3314 and A375 cells (Fig. 2D). We found that
Parkin induces apoptosis, since overexpression in both
WM3314 and A375 melanoma cells increased the percentage
of apoptotic and TUNEL-positive cells compared to cells
transfected with empty vector (Fig. 2E and F). These results
clearly demonstrate that Parkin reduces proliferation and
promotes apoptosis in melanoma cells, suggesting that loss-of-
function mutations in Parkin enable melanoma cells to avoid
cell cycle arrest and proliferate.Parkin-E28K melanoma somatic mutation perturbs
Parkin biological activity in melanomaTo determine the effects of the identified melanoma-specific
mutations on Parkin function, we generated expression vec-
tors of each melanoma-specific Parkin mutant. We first
examined the ubiquitin ligase activity of these mutants by
testing and comparing the ubiquitination capacity of wild-type
(WT) Parkin and Parkin mutants C360S, E300K, L112F,
R275W, and E28K in the presence or absence of a proteasome
inhibitor (MG132). In the absence of MG132, less ubiquiti-
nation activity was detected upon expression of WT Parkin.
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Fig. 1. Somatic mutations of the Parkin gene in human melanoma patients.
A: Schematic diagram of Parkin protein with boundaries of the 12 exons and protein domains indicated. Locations of mutations and the corresponding amino acid
changes are shown; missense mutations are shown in purple, synonymous mutations in black. The sizes of purple spheres represent the frequency of mutations in
Parkin exons in PD patients. The numbers 1e12 indicate the exon number. The dashed lines mark the borders of each exon in relation to the protein domains. B:
Melanoma mutations in the UBL, RING and IBR domains of Parkin, shown as spheres on cartoon depictions of the different domains (colored as in panel A). Gray
spheres represent zinc atoms. The framed diagrams show enlargements of the regions of different mutated positions. The enlargment at the lower right shows the
structure of a homolog, NEDD8, bound to its partner NAE1, highlighting the potential importance of E28 for proper interactions with partners. Structures were
rendered using Pymol (http://www.pymol.org).
372 L. Levin et al. / Journal of Genetics and Genomics 43 (2016) 369e379This was likely due to higher levels of degradation of the
ubiquitinated substrates by the proteasome. Of the Parkin
mutants evaluated, only Parkin-E28K had significantly lower
ubiquitination capacity than WT Parkin (Fig. 3A). Since only
E28K in the UBL domain abolished Parkin ubiquitination
activity (Fig. 3A), we proceeded with this mutation for further
functional characterization of Parkin. Structural analysis of a
homolog of Parkin ubiquitin-like domain, NEDD8, bound to
NAE1, shows that this residue is conserved, and that it forms a
salt-bridge with NAE1 residue R251. Therefore, we speculate
that E28 is important for the interaction with a partner during
the ubiquitination process.
To further evaluate the biological activity of Parkin-E28K,
WM3314 melanoma cells were transfected with vectors for the
expression of WT Parkin or Parkin-E28K, and proliferation
rates were measured relative to cells transfected with a control
vector. Cells that expressed WT Parkin grew more slowly than
control cells, and cells that expressed Parkin-E28K prolifer-
ated significantly more rapidly than the control cells (Fig. 3B).
The overexpression of Parkin-E28K resulted in an enhancedcell cycle progression of both WM3314 and A375 cells
(Fig. 3C and S1). Finally, the E28K mutation impaired Parkin
biological activity as an apoptosis inducer in WM3314 mel-
anoma cells (Fig. 3D and S1). These data demonstrate that in
melanoma, a glutamic acid located at the consensus position
28 of Parkin is essential for the E3 ligase activity of Parkin and
thus for its biological function as an inhibitor of proliferation
and an apoptosis inducer.Parkin interactors in melanomaIn order to further explore the molecular mechanism of Parkin
activity in melanoma, we identified Parkin substrates using
mass spectrometry analysis. WM3314 melanoma cells were
transfected with an expression vector of GFP-tagged-Parkin or
with a GFP control vector. Following immunoprecipitation of
GFP-Parkin with anti-GFP antibody (Fig. 4A, left panel),
associated proteins were identified using mass spectrometry
analysis. The experiment was repeated twice to increase the
significance of the results. Parkin interacting proteins that
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Fig. 2. Parkin reduces melanoma proliferation and promotes apoptosis.
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373L. Levin et al. / Journal of Genetics and Genomics 43 (2016) 369e379were identified in two independent experiments (Table S2), are
represented in a functional protein association network con-
structed using STRING in Fig. S2. As expected, since Parkin
is a known E3 ubiquitin ligase (Moore et al., 2008), the ma-
jority of identified proteins are associated with the ubiquiti-
nation process and are components of the 26S proteasome
system, which strengthen the validity of our analysis. Addi-
tionally, four known Parkin substrates were identified in ourmass spectrometry analysis, HSP70 (Moore et al., 2008), alpha
and beta Tubulin (Ren et al., 2003) and VDAC1 (Narendra
et al., 2010). Importantly, this is the first time that these sub-
strates are identified as Parkin interactors in melanoma. In line
with our experimental results, gene ontology analysis revealed
a significant enrichment of cell cycle regulators and mito-
chondrial proteins (Fig. 4B and Table S3), emphasizing the
role of Parkin-E3 ligase in melanoma cell cycle regulation.
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A: Ubiquitination assay. HEK293 cells were co-transfected with vectors for expression of myc-tagged Parkin or mutant Parkin and HA-tagged ubiquitin in the
presence or absence of MG132. Parkin was immunoprecipitated, and ubiquitination was detected by anti-HA (a-HA). Staining with anti-b-actin was used as a
loading control. B: Crystal violet staining. WM3314 were transfected with WT Parkin, Parkin-E28K, or control vectors. Cells were stained with crystal violet, and
the color intensity was measured. Data are relative to color levels on day 0. Error bars represent SEM, * indicates P < 0.05 (n ¼ 3). C: Cell cycle analysis. Data
are represented as G1 phase relative to G2/M phase. Error bars represent SEM, * indicates P < 0.05 (n ¼ 3). D: TUNEL labeling analysis using a fluorescence
microscope. Cells were subjected to serum-free medium and were labeled with TUNEL (red) and DAPI (blue).
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The co-occurrence of PD and melanoma has been reported in
several epidemiological studies (Olsen et al., 2006; Gao et al.,
2009), and recently in a genetic study (Hu et al., 2016);
however, the molecular link is still unknown. To the best of
our knowledge, no study has stratified PD patients by common
PD mutations (Parkin, DJ-1, SNCA, etc.) and looked for
melanoma appearance in each group. Epidemiologically, only
a positive correlation between the two diseases has been re-
ported. For many years, melanoma appearance in PD patients
was thought to be related to levodopa treatment (Fiala et al.,
2003). It was shown that levodopa treatment does notincrease the risk of melanoma (Fiala et al., 2003), and the risk
for melanoma is increased before PD is diagnosed (Olsen
et al., 2006). Thus, it is reasonable that the joint susceptibil-
ity for both diseases is based on genetic components. Here we
focus on Parkin as a plausible candidate underlying the PD-
melanoma link. Germline mutations in the Parkin gene are
major cause of the familial forms of PD (Lu¨cking et al., 2000),
and mutations or deletions of Parkin promote various types of
cancers development (Veeriah et al., 2010). We discovered five
somatic missense mutations in the Parkin gene in human
melanoma samples; these mutations map to regions where the
majority of Parkin mutations were located in PD patients. In
our analysis, one of the mutations, Parkin-E28K, nearly
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Fig. 4. Parkin interactors in melanoma cells.
A: WM3314 cells were transfected with GFP-tagged Parkin or with control
vector. Cells were treated with MG132 for 4 h, followed by immunoprecipi-
tation with anti-GFP. Protein complexes were detected with anti-Parkin and
were subjected to mass spectrometry analysis. B: GO terms enriched in the
identified Parkin interacting proteins.
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located in the UBL domain, and thus probably disrupts sub-
strate binding. Another UBL located mutation R42P was re-
ported previously to be involved in PD, and was shown to
potentially disrupt binding to the proteasome (Sriram et al.,
2005).
In PD, there is massive loss of dopaminergic neurons in the
substantia nigra (Lim et al., 2005; Hampe et al., 2006; Oyama
et al., 2010), whereas cancer cells are characterized by un-
controlled cell division and growth (Hanahan and Weinberg,
2011). Parkin is expressed in a wide variety of tissues and is
well conserved from nematodes to humans (Xu et al., 2014).
Although Parkin inactivation has mostly been shown to cause
neuronal dysfunction, it is reasonable that it will also affect
other tissues. Indeed, Parkin alterations are involved in various
types of cancer (Veeriah et al., 2010), supporting a central role
for Parkin in various tissues. It appears, therefore, that muta-
tions in Parkin cause different phenotypes in different cell
lineages. This contradiction might be due to various Parkin
regulators and substrates in different cell types, in accordance
with the different cellular roles, function, differentiation state,
proliferative capacity and other unique features of each cell
type. One prominent difference between cancer cells and
neurons is their ability to progress through cell cycle. Neurons
are fully differentiated post mitotic cells that do not prolifer-
ate, whereas cancer cells partly lose their differentiation state
and retain high proliferative capacity (Hanahan and Weinberg,2011). This may indicate that cell proliferative state dictates
the opposite outcomes of Parkin function. In accordance with
previous works demonstrating that Parkin functions as a tumor
suppressor (Veeriah et al., 2010; Yeo et al., 2012), we showed
here that Parkin expression decreased the ability of melanoma
cells to progress through cell cycle and inhibited proliferation.
In addition, the mutant Parkin-E28K could not suppress, and
possibly promote melanoma cell cycle progression. As
differentiated neurons that receive signals for proliferation die
(Sumrejkanchanakij et al., 2006), it will be interesting to
examine whether Parkin functions as a kind of a cell cycle
guardian to prevent neuronal cells from entering cell cycle,
and its absence causes re-entrance to cell cycle leading to
apoptotic cell death.
In melanoma, Parkin expression results in increased
apoptotic cell death; this was not observed when the Parkin-
E28K mutant was expressed. These results are contradictory
to numerous previous reports that intact Parkin is required for
neuronal survival and health, and that dysfunctional Parkin
leads to neuronal death (Shen and Cookson, 2004), like in PD.
Taken together, however, these results strongly support the fact
that mutated Parkin leads to opposite phenotypes in different
lineages.
In our study, we focus on the effect of the E28K variant in
melanoma cells, since it is the only mutation that perturbed
Parkin E3-ligase ubiquitination activity in our prior
biochemical assays. However, other mutations that were
identified here, including the R275W variant, may also impair
Parkin activity and induce changes of cellular phenotypes. For
example, Sriram et al. (2005) have previously demonstrated
that the R275W variant does not impair Parkin E3-ligase
ubiquitination activity. Additionally, Xiong et al. (2015) re-
ported on the presence of germline R275W mutation in fa-
milial lung cancer patients. It will be very interesting to further
investigate the effect of each mutation on intracellular local-
ization, substrate binding and degradation, solubility, and
enzymatic activity.
Interestingly, the majority of Parkin mutations we identified
did not decrease, and even elevated, the ubiquitination activity
of Parkin (Fig. 3A and 3A). Additionally, differences in
extracting expressed mutants from lysed cells were observed.
Specifically, Parkin mutants do not appear equally in the
Triton X-100 soluble fraction, whereas roughly similar
amounts of each mutant were detected in the sodium dodecyl
sulfate lysis buffer (Fig. S3B). The lysate generated by SDS
buffer includes whole cell content, whereas the lysate gener-
ated by Triton X-100-based buffer includes only the soluble
fraction, as the insoluble fraction (including cell membranes)
are excluded from the final analysis. Specifically Parkin-
R275W, E300K, and C360S were not soluble in Triton X-
100 when compared with WT Parkin (Fig. S3B, lower panel).
Importantly, all Parkin mutant mRNAs were expressed at
similar levels (Fig. S3C). These observations suggest that
some mutations of Parkin may change the protein cell local-
ization (Sriram et al., 2005); alternatively, mutation might lead
to a conformational change, thus affecting protein solubility,
and possibly protein activity.
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and melanoma by using somatic mutations data of melanoma
patients. Of note, Parkin mutations in PD patients are germline
(Kahle and Haass, 2004; Guo et al., 2008, 2010). Recently, Hu
et al. (2016) published a work in which they identified Parkin
germline mutations in melanoma patients; the results are in
line with what we propose here, and further demonstrate the
genetic connection between melanoma and PD. It is highly
likely that germline PD mutations in Parkin play a role in
melanoma predisposition, either in the initial development of
the tumor or its progression. Interestingly, most of the Parkin
somatic mutations found in variety of cancers (Veeriah et al.,
2010) occur at the same domains and residues as the germ-
line Parkin mutations implicated in PD. In addition, although
Parkin KO mice do not recapitulate signs central to Parkin-
sonism, these mice are prone to cancer development (Fujiwara
et al., 2008). Mice with homozygote Parkin exon 3 deletions
spontaneously develop hepatic tumors with characteristics of
hepatocellular carcinoma (HCC). Moreover, Parkin heterozy-
gous deletion accompanied by APC heterozygous deletion
promotes intestinal adenoma development in mice. As HCC
appears in the mice at advanced age, and there is a dependency
between Parkin and APC mutations in adenoma development,
it is possible that a mutation in Parkin alone is not sufficient to
initiate development of some types of cancer, and it may
require additional risk factors. Moreover, we identified Parkin
interacting proteins in melanoma cells by immunoprecipita-
tion followed by mass spectrometry. The proteins detected are
mainly connected to cell cycle, mitochondrial function, and
proteasome function; this result is consistent with the study of
Sarraf et al. (2013). In conclusion, our data indicate that Parkin
has a tumor suppressive role in melanoma. Our findings open
new possible methods for early diagnosis and treatments
against both diseases.
MATERIAL AND METHODSCell culture and transfectionWM3314 and A375 melanoma cells were generously provided
by Dr. Levi A. Garraway (Department of Medical Oncology
and Center for Cancer Genome Discovery, Dana-Farber Can-
cer Institute, Boston, MA, USA). Cells were cultured in
DMEM medium supplemented with 10% fetal bovine serum
(FBS, Sigma-Aldrich, USA) and 1% penicillin/streptomycin/
glutamine (Invitrogen, USA). For establishment of stable cell
lines, A375 cells were transfected with a vector for expression
of WT Parkin-FLAG or control vector, and were selected by
culture with 100 mg/mL G418 (SigmaeAldrich). Constructs
were transfected using jetPEI according to the manufac-
turer’s instructions.Plasmids and cloningSite-directed mutagenesis was performed using the Stratagene
Quick Change method (Stratagene, USA) according to man-
ufacturer’s protocol. pEGFP-N1 and pEGFP-C2 vectors werepurchased from Clontech (USA). The pRK5-Parkin-myc
expression vector is a gift from Dr. Simone Englender (The
Rapport Institute for Research, Faculty of Medicine, Technion
e Israel Institute of Technology, Haifa, Israel). The
pcDNA3.1-Parkin-FLAG expression vector was kindly pro-
vided by Dr. Luc Morris (Memorial Sloan-Kettering Cancer
Center, New York, NY, USA). To tag Parkin with GFP, a
fragment spanning the WT or mutant Parkin coding region
was amplified from RSK-Parkin constructs, digested with
EcoR I-SAL I, and cloned into pEGFP-C2.Colony-forming assayCells were selected using G418 until visible separated col-
onies were formed. Cells were then fixed with 10% acetic acid
and 10% ethanol for 40 min. Colonies were stained with 0.2%
(w/v) crystal violet (SigmaeAldrich) in 10% acetic acid and
10% ethanol for 1 h, washed, and counted.Crystal violet stainingCells were washed with PBS and fixed with 10% acetic acid
and 10% ethanol solution. Cells were then stained using 0.2%
(w/v) crystal violet in 10% acetic acid and 10% ethanol for
1 h. For quantification of the crystal violet staining, the dye
was re-dissolved in 10% acetic acid solution. Color intensity
was measured using a UVevis plate reader at 595 nm.Mitochondrial activity assayCells were treated with activated XTT solution (Biotium,
USA). The signal was measured according to the manufac-
turer’s protocol at 490 nm and normalized to signal at 690 nm.Cell cycle analysisCells were synchronized in G1 phase by treatment with
2 mmol/L thymidine (SigmaeAldrich) for 22 h. Cells were
then washed twice with PBS and incubated for 18 h in DMEM
with 10% serum. Cells pellets were fixed with 70% ice cold
ethanol and resuspended in propidium iodide (PI) solution
containing 0.05% Triton X-100, 0.05 mg/mL PI (Sigma-
eAldrich), and 0.1 mg/mL of RNase A. Cell cycle phases
were determined using a BD FACSCalibur flow cytometer and
analyzed by Kaluza analysis software.Annexin-PI stainingStress was induced by growing cells in serum-free medium for
48 h. The cell pellets were suspended in binding buffer con-
taining 0.1 mol/L HEPES, pH 7.4, 1.4 mol/L NaCl, and
25 mmol/L CaCl2. To 10
5 cells, 1 mg/mL of Annexin V
(Biolegend, USA) and 0.05 mg/ml PI were added. Samples
were incubated in the dark at room temperature for 15 min
then analyzed on a BD FACSCalibur flow cytometer with
Flowjo analysis software. Samples treated with Annexin V
only and PI only were used as controls.
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for 48 h. Cells were fixed in 4% PFA for 1 h at room tem-
perature and then incubated on ice for 2 min in per-
meabilization solution containing 0.1% Triton X-100 in 0.1%
sodium citrate. Cells were then incubated with TUNEL re-
action mixture (in situ cell death detection kit, Roche, USA)
for 1 h and then stained with 406-diamidino-2-phenylindole
(DAPI) (SigmaeAldrich). Cells were analyzed by fluores-
cence microscopy.Gel electrophoresis, immunoblotting, and
immunoprecipitationCells were lysed 48 h after transfection in buffer containing
50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 0.5% Triton X-
100, 1 mmol/L EDTA, and protease inhibitor cocktail (Sig-
maeAldrich). For Input, cells were resuspended in 4% SDS,
0.1 mol/L Tris pH 7.5. Once protein concentration was
determined, 0.1 mol/L DTT was added to the lysate. Samples
were resolved by SDS-PAGE, transferred to nitrocellulose
membranes, and exposed to the appropriate antibodies: mouse
anti-hParkin (MAB14381; R&D Systems, USA), mouse anti-
b-actin (AC-74; SigmaeAldrich), and rat anti-HA (3F10;
Roche, Switzerland). Proteins were visualized with Super-
SignalChemiluminescent Substrates (Pierce, USA) using
horseradish peroxidase-conjugated anti-mouse secondary
antibody (7076; Cell Signaling, USA) or goat anti-rat (sc-
2006; Santa Cruz Biotechnology, USA).Ubiquitination assayFor ubiquitination assay, HEK293 cells were co-transfected
with constructs for expression of WT or mutant myc-tagged-
Parkin or control vector and with HA-tagged ubiquitin, fol-
lowed by immunoprecipitation of Parkin with anti-myc.
Ubiquitination was detected by anti-HA. MG132 (Sigma-
eAldrich) treatment was done at 10 mmol/L for 4 h before
harvest.Sample preparation for mass spectrometry analysisWM3314 cells were transfected with GFP-tagged-Parkin or
with control vector. After 48 h, cells were incubated for 4 h
with 20 mmol/L MG132 and then washed twice with PBS.
Cells were lysed in lysis buffer containing 150 mmol/L NaCl,
50 mmol/L Tris pH 7.5, 1% NP-40, 1 mmol/L Na3VO4,
1 mmol/L NaF, 0.1% b-mercaptoethanol, and protease in-
hibitor. Proteins were incubated with mouse anti-GFP anti-
body (SC-9996; Santa Cruz Biotechnology, USA) for 18 h at
4C and then incubated with protein A/G agarose beads for
2 h at 4C. Proteins were eluted in 50 mmol/L Tris, pH 8.5,
8 mol/L urea, and 1 mmol/L DTT for 2 h and in 50 mmol/L
Tris, pH 8.5, 8 mol/L urea, and 5 mmol/L IAA for 5 min,
followed by overnight incubation at room temperature in the
dark.Mass spectrometry analysisThe tryptic peptides were desalted over C18 resin, dried, and
resuspended in 0.1% formic acid. The peptides were separated
by reversed-phase chromatography on 0.075  180-mm fused
silica capillaries (Agilent J&W, USA) packed with Reprosil
reversed-phase material (Dr. Maisch GmbH, Germany). The
peptides were eluted using a linear 60-min gradient of 5%e28%
solvent A, 15-min gradient of 28%e95% solvent A, and 15 min
solvent B. Solvent A was 95% acetonitrile with 0.1% formic
acid in water and solvent B was water. The flow rate was
0.15 mL/min. Mass spectrometry was performed by Q Exactive
plus mass spectrometer (Thermo Scientific, USA) in a positive
mode using repetitively full MS scan followed by collision
induced dissociation of the 10 most dominant ions selected
from the first MS scan. The mass spectrometry data from two
biological repeats was analyzed using Proteome Discoverer 1.4
software with Sequest (Thermo Scientific, USA) and Mascot
(Matrix Science, UK) algorithms against Human Uniprot
database with 1% FDR. Semi-quantitative analysis was done by
calculating the peak area of each peptide based its extracted ion
currents, and the area of the protein was calculated as the
average of the three most intense peptides from each protein.
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